BTHS is an X-linked cardiac and skeletal mitochondrial myopathy caused by mutation of the gene encoding tafazzin 1 , an acyltransferase responsible for normal acylation of cardiolipin, the major phospholipid of the mitochondrial inner membrane 2 (Supplementary Fig. 1 ; data tables for supplementary data are available as Supplementary Data Sets). Cardiolipin abnormalities also occur in ischemic heart disease and aging and have been implicated in the cardiac dysfunction characteristic of these conditions 3 . The mechanisms that lead from abnormal cardiolipin biogenesis to cardiomyopathy are not well understood. Here, we combined patient-derived iPSCs, genome editing, modified RNA (modRNA) 4 and bioengineered microchips that simulate myocardial tissue ('heart-on-chip') 5 to replicate the pathophysiology of BTHS cardiomyopathy in tissue constructs. Using these approaches, we identified mitochondrial functional abnormalities caused by TAZ mutation and cardiolipin deficiency. We show that TAZ mutation is necessary and sufficient to disrupt sarcomere assembly and contractile stress generation and that these functional abnormalities are not due to global ATP depletion. Furthermore, we show that the BTHS cardiomyopathic phenotype is readily reversed by re-introduction of wild-type (WT) TAZ or by suppression of excessive reactive oxygen species (ROS) produced by BTHS mitochondria. These results provide new insights into the links between mitochondrial function, sarcomere assembly and muscle contractile activity and suggest new therapeutic strategies for BTHS.
These iPSC lines had normal karyotype and met pluripotency criteria (Supplementary Fig. 2 ; all cell lines in this study are summarized in Supplementary Table 1) . As controls, we used three normal iPSC lines, generated by retroviral (WT1 and WT2) or modRNA (WT3) reprogramming (Supplementary Table 1 ). We carried out the experiments presented below multiple times and using multiple cell lines with consistent results; we provide representative data in the accompanying figures and supplementary information and an overview of the data collected in Supplementary Table 2 .
We differentiated the iPSCs into iPSC-CMs using an established protocol 9 ( Supplementary Fig. 3a-c) , and then used magnetic cell sorting for the cardiomyocyte surface marker vascular cell adhesion molecule-1 (VCAM-1) 10, 11 to obtain preparations containing ~80% iPSC-CMs ( Supplementary Fig. 3d-f ). On replating, the enriched myocytes formed sheets of cardiomyocytes ( Supplementary Fig. 3g ) that beat spontaneously (Supplementary Movie 1) .
BTHS is characterized by depletion of mature cardiolipin and accumulation of an immature form, monolysocardiolipin ( Supplementary  Fig. 1 ) 12, 13 . Phospholipid profiles of BTHS iPSC-CMs, measured by mass spectrometry, confirmed that abnormal cardiolipin processing was recapitulated in BTHS iPSC-CMs (Fig. 1a) . The monolysocardiolipin-to-cardiolipin ratio in BTHS iPSC-CMs exceeded 0.3, the clinically used diagnostic threshold for BTHS 13 (Fig. 1a,b) . Thus, BTHS iPSC-CMs exhibited impaired cardiolipin biogenesis that matched what is observed clinically in patients with BTHS.
We assessed mitochondrial morphology and function in BTHS iPSC-CMs. FACS analysis showed that BTHS iPSC-CMs had mitochondrial numbers similar to those of control iPSC-CMs and that BTHS iPSC-CM mitochondria were smaller than control mitochondria ( Supplementary Fig. 4a,b) . This smaller size was associated with greater fragmentation of BTHS iPSC-CM mitochondria compared to the more highly networked mitochondria of controls ( Supplementary Fig. 4c ). To assess BTHS mitochondrial function, we cultured iPSC-CMs in galactose-based medium, which has limited ability to support ATP production via glycolysis 14 . Under these conditions, BTHS iPSC-CM ATP levels were significantly lower than those of wild-type iPSC-CMs (Fig. 1c) . Consistent with cellular energy deprivation, the activated form of AMP-dependent kinase was markedly upregulated in BTHS iPSC-CMs ( Supplementary  Fig. 5a ). Next, we used an extracellular flux analyzer to probe mitochondrial function (the approach and the terms used are described in Supplementary Fig. 5b,c) . BTHS iPSC-CMs unexpectedly exhibited an elevated basal oxygen consumption rate, which was a result of both increased F 1 F 0 ATP synthase oxygen consumption and increased 'H + leak' (Fig. 1d,e and Supplementary Fig. 5d ). In the context of reduced basal ATP levels, these data pointed to inefficient F 1 F 0 ATP synthase activity, which we confirmed by selective complex immunocapture followed by measurement of F 1 F 0 ATP synthase quantity and activity (Supplementary Fig. 5e ). We also measured respiratory capacity, which reflects maximal electron transport chain activity, and found that it was severely impaired in BTHS iPSC-CMs (Fig. 1d,e) .
Collectively, these data demonstrate that TAZ deficiency and consequent cardiolipin abnormalities reduce peak electron transport chain function and decrease ATP generation efficiency by lowering F 1 F 0 ATP synthase-specific activity. The metabolic abnormalities of BTHS iPSC-CMs were not evident in BTHS primary fibroblasts or iPSCs ( Supplementary Fig. 5f,g ), consistent with the muscle-selective phenotype of patients with BTHS.
Cardiomyocytes are capable of producing ATP through both glycolysis and oxidative phosphorylation. We hypothesized that glucose, an npg energy source that supports both glycolysis and oxidative phosphorylation, would normalize ATP levels. Indeed, glucose induced glycolysis and triggered a metabolic shift away from oxidative phosphorylation in both BTHS and control iPSC-CMs ( Supplementary  Fig. 5h,i) . This metabolic shift normalized BTHS iPSC-CM ATP levels and basal oxygen consumption rate ( Fig. 1f and Supplementary  Fig. 5j ). However, glucose culture did not correct the markedly depressed respiratory capacity of BTHS iPSC-CMs ( Supplementary  Fig. 5j ). These observations indicate that glucose restores basal ATP levels through increased glycolysis but does not correct underlying mitochondrial defects in the electron transport chain.
TAZ mutation causes BTHS iPSC-CM phenotypes
Because iPSCs derived from patients with BTHS and control iPSCs have numerous genetic differences other than TAZ mutation, we took three independent approaches to further establish the causative role of TAZ mutation in abnormal cardiolipin biogenesis and mitochondrial function. First, we used adenoviral delivery of TAZspecific short hairpin RNAs (shRNAs) to deplete TAZ in neonatal rat ventricular cardiomyocytes (NRVMs) by over 80% at 72 h after infection (Supplementary Fig. 6a ). At this time point, cardiolipin profiles in NRVMs with TAZ knockdown were already highly abnormal ( Supplementary Fig. 6b ), indicating rapid turnover of TAZ and mature cardiolipin. As in BTHS iPSC-CMs, TAZ deficiency in NRVMs grown in galactose reduced ATP levels, activated AMPdependent kinase ( Supplementary Fig. 6c,d ) and caused comparable abnormalities in mitochondrial function (Supplementary Fig. 6e ). Electron microscopy did not reveal alterations in mitochondrial morphology or number in this short-term TAZ depletion experiment ( Supplementary Fig. 6f ), suggesting that mitochondrial functional abnormalities are not contingent upon the mitochondrial structural abnormalities observed in patients with BTHS. Second, we used modRNA technology 4, 7, 15 in which 5-methylcytidine and pseudouridine are substituted for cytidine and pseudouridine, respectively, to efficiently re-introduce TAZ into BTHS iPSC-CMs.
Cardiomyocytes, including iPSC-CMs, are refractory to standard transfection methods. modRNA has minimal toxicity 4, 7, 15 and efficiently transfects cardiomyocytes 16 (Supplementary Fig. 7) . TAZ modRNA likewise transfected iPSC-CMs, and TAZ protein localized to mitochondria (Fig. 2a) . TAZ modRNA restored cardiolipin biogenesis and normalized basal mitochondrial function in BTHS iPSC-CMs, although maximal respiratory capacity was rescued incompletely (Fig. 2b-e) . These results indicate that TAZ mutation is necessary to confer the BTHS mitochondrial phenotype and that this phenotype is rapidly reversed upon TAZ restoration.
Third, we used Cas9-mediated scarless genome editing 17 to mutate TAZ in the control human iPSC line PGP1-iPSC, yielding three iPSC lines that are isogenic except for the sequence of TAZ exon 6 (Supplementary Table 1 and Fig. 3a-c ; the Online Methods and Supplementary Fig. 8 contain details on the construction and validation of these iPSC lines). PGP1-TAZ c.517delG contains the TAZ frameshift mutation from the BTH-H line (1-nt deletion), and PGP1-TAZ c.517ins contains a distinct frameshift mutation at the same site (14-nt insertion; Fig. 3a-c) . PGP1-TAZ WT is a control line that was handled identically to the PGP1-TAZ c.517delG and PGP1-TAZ c.517ins lines but contains a WT TAZ sequence. iPSC-CMs derived from these isogenic TAZ mutant lines fully recapitulated the cardiolipin, mitochondrial and ATP deficits that we observed in patient-derived iPSC and NRVM TAZ knockdown models (Fig. 3d-g and Supplementary Table 2) . Together, these data indicate that TAZ mutation alone is sufficient to cause these defects in an otherwise unaffected genetic background.
Abnormal sarcomerogenesis in BTHS iPSC-CMs
Mitochondria regulate cardiomyocyte maturation 18 , a hallmark of which is assembly of organized arrays of sarcomeres. We noticed that BTH-H iPSC-CMs grown on an unpatterned gelatin substrate assembled sarcomeres more irregularly than did control iPSC-CMs. To compare sarcomere architecture more precisely, we engineered npg iPSC-CM shape by seeding the cells on micropatterned fibronectin rectangles designed to mimic the dimensions of human adult cardiomyocytes 19 , with length/width ratios of approximately 7:1 (95 µm × 13 µm). To quantify the global regularity of sarcomere arrangement, we developed an unbiased metric to score images of patterned iPSC-CMs immunostained for the sarcomere protein α-actinin. This metric, which we named sarcomere organization, is based on the regularity of sarcomere spacing, as determined from two-dimensional (2D) Fourier spectra of the sarcomere immunostains ( Supplementary Fig. 9a -c and Online Methods). Whereas sarcomeres in control iPSC-CMs extended serially along the entire length of the cell, sarcomeres in BTH-H iPSC-CMs were intermittent and sparse (Fig. 4a) . Treatment with TAZ modRNA restored sarcomere regularity (Fig. 4a ). These differences were reflected in the sarcomere organization metric, which was lower in BTH-H iPSCCMs than in controls and was increased by TAZ modRNA treatment (Fig. 4a) . Although glucose culture normalized ATP levels to a degree comparable to that achieved with TAZ modRNA, glucose culture did not rescue sarcomere formation (Fig. 4a) . These defects in sarcomere assembly were recapitulated in genome-edited PGP1-TAZ c.517delG and PGP1-TAZ c.517ins iPSC-CMs but were not observed in isogenic PGP1-TAZ WT controls ( Fig. 4b) , confirming the causative role of the BTH-H exon 6 frameshift TAZ mutation. These data suggest that sarcomerogenesis is sensitive to mitochondrial function independently of whole-cell ATP levels. Notably, BTH-C iPSC-CMs exhibited sarcomere organization that was not significantly different from that of controls (Fig. 4c) . This phenotypic heterogeneity between BTH-H and BTH-C iPSC-CMs may be due to the nature of the specific TAZ mutations or to other variables between the cell lines. Further use of genome-edited cell lines will be necessary to better understand genotype-phenotype relationships in this disease.
Heart-on-chip model of BTHS myopathy and its genetic rescue Because patients with BTHS often develop cardiomyopathy, we asked whether we could replicate the contractile pathophysiology of BTHS in an in vitro model of engineered myocardium and demonstrate the efficacy of TAZ modRNA treatment in this model. Toward this goal, we used our heart-on-chip assay 5, 20 to quantitatively measure the contractility of engineered myocardial tissue assembled from BTHS or control iPSC-CMs. iPSC-CMs selected via magnetic-activated cell sorting (MACS) were seeded onto thin elastomers micropatterned with fibronectin lines and supported by glass coverslips 21, 22 . Over a 5-d culture period, the iPSC-CMs self-organized into laminar anisotropic myocardium. Staining for sarcomeric α-actinin in control iPSC-CM-containing tissue revealed both aligned sarcomeres and fibrous structures indicative of the relatively immature phenotype of iPSC-CMs (Fig. 5a) , findings that are similar to previous observations in immature primary rat cardiac myocytes 23 . Like individual iPSC-CMs seeded on fibronectin rectangles, engineered BTHS iPSC-CM-containing tissue exhibited impaired sarcomere assembly compared to controls (Supplementary Fig. 10a ). We then peeled precut muscular thin film (MTF) tissue constructs from the glass substrate, allowing them to contract and curl away from the plane of the coverslip ( Fig. 5a and Supplementary Movie 2). We used movies of contracting MTFs to calculate radii of curvature, from which we calculated the diastolic and peak systolic stresses using a modification of Stoney's equation 5, 21, 24 . Twitch stress was calculated as the difference Fig. 5b,c) . n = 3. **P < 0.01 by one-way analysis of variance (ANOVA) with Dunnett's post hoc test compared to PGP1-TAZ WT + nGFP. Data are expressed as mean ± s.e.m.
npg between diastolic and peak systolic stress (Fig. 5a) . During electrical field stimulation, control iPSC-CM MTFs contracted rhythmically at frequencies ranging from 1 to 5 Hz (Fig. 5b, Supplementary  Fig. 10b and Supplementary Movie 2). BTH-H iPSC-CM tissues developed significantly lower twitch and peak systolic stress compared to controls over the same stimulation frequency range, indicating that BTHS engineered myocardial tissue recapitulates the BTHS myopathic phenotype. Next, we asked whether these engineered myocardial tissue constructs effectively model disease correction. Treatment of BTH-H iPSC-CMs (Fig. 5b, Supplementary Fig. 10 and Supplementary Movie 2) with TAZ modRNA for 5 d restored contractile function of MTF tissue constructs to levels comparable to those of controls, further confirming that this myopathic phenotype is reversible and due to TAZ mutation.
We assessed the contribution of whole-cell ATP to BTHS contractile dysfunction by culturing engineered iPSC-CM MTF constructs in glucose-containing medium, which we showed above increases ATP in BTHS iPSC-CMs to a level comparable to that seen with TAZ modRNA treatment. In contrast to TAZ modRNA rescue, glucose culture alone did not restore BTH-H iPSC-CM MTF force generation at any tested stimulation frequency (Fig. 5b, Supplementary Fig. 10b ,c and Supplementary Movie 3). Although local pools of mitochondrially produced ATP might theoretically be required for iPSC-CM force generation, such a mechanism is unlikely because inhibition of mitochondrial ATP production with oligomycin in control iPSC-CM MTFs did not alter their contractile strength ( Supplementary Fig. 11) ; this finding is consistent with the immature and highly glycolytic properties of iPSCCMs. Together, these data show that BTH-H iPSC-CMs have a severe defect in contractility that occurs independently of ATP depletion.
This result is consistent with anectodal data we obtained from a patient with BTHS that showed preserved cardiac high-energy phosphate levels in the setting of impaired heart function ( Supplementary Fig. 12 ). Taken together, these data suggest that contractile dysfunction in BTHS occurs despite normal myocardial energy stores.
We next reproduced the findings from patient-derived BTHS iPSCCMs in the isogenic, genome-edited cells. Contractile function of mock-manipulated PGP1-TAZ WT iPSC-CM myocardial constructs was equivalent to that of constructs derived from the parental PGP1 cell line, whereas constructs derived from TAZ mutation-containing iPSC-CMs (PGP1-TAZ c.517delG or PGP1-TAZ c.517ins ) caused severe loss of contractile stress generation (Fig. 5c, Supplementary Fig. 10c and Supplementary Movie 4) . Re-introduction of TAZ by modRNA restored contractility to mutant tissue constructs (Fig. 5c,  Supplementary Fig. 10c and Supplementary Movie 4) . Thus, in both patient-derived cells and cells with an isogenic background, TAZ deficiency causes contractile dysfunction.
BTH-C myocardial tissue constructs also showed poor contractile function, which was reflected in their markedly reduced beating activity (Supplementary Movie 2) and severely depressed twitch stress (Fig. 5d) . Systolic stress generation was also reduced significantly in BTH-C myocardial tissue constructs compared to controls (Fig. 5d) . However, their peak systolic (and diastolic) stresses were substantially higher than in their BTH-H counterparts (Fig. 5b,d) , perhaps reflecting the difference in sarcomere assembly that we observed between these TAZ genotypes (Fig. 4a,c) .
Assessment of potential therapies using BTHS iPSC-CMs
We used BTHS iPSC-CMs to measure the effect of three proposed interventions for BTHS: bromoenol lactone, an inhibitor of npg mitochondrial phospholipase A 2 , which catabolizes mature cardiolipin 25 ; linoleic acid (LA), an essential unsaturated fatty acid precursor of mature cardiolipin 26 ; and arginine plus cysteine, amino acids that are frequently deficient in patients with BTHS 27 . LA and bromoenol lactone partially corrected the monolysocardiolipin/cardiolipin ratio in BTHS iPSC-CMs, whereas arginine plus cysteine had no effect (Fig. 6a) . Treatment of galactose-cultured BTHS iPSC-CMs with LA or arginine plus cysteine increased ATP to levels comparable to those seen in control iPSC-CMs or BTHS iPSC-CMs rescued with TAZ modRNA, whereas bromoenol lactone had no significant effect (Fig. 6b) . LA, but not arginine plus cysteine, also normalized the basal and F 1 F 0 ATP synthase oxygen consumption rates of BTHS iPSC-CMs but had little effect on maximal mitochondrial respiratory capacity ( Fig. 6c and Supplementary Fig. 13 ). Thus, of the three tested treatments, LA was most effective at correcting the metabolic phenotype of BTHS iPSC-CMs.
Because LA had a positive effect in each of these metabolic assays, we asked whether LA supplementation could mitigate the sarcomere organization and contractile defects of BTHS iPSC-CMs. LA improved the sarcomere organization of BTH-H iPSC-CMs (Fig. 6d) . No statistically significant improvement was noted in BTH-C iPSC-CMs, whose sarcomeric organization was not significantly different from that of controls. In both BTH-H and BTH-C myocardial tissue constructs, LA dramatically increased twitch stress to nearly normal levels (Fig. 6e) . This was reflected in an obvious effect of LA on rhythmic beating of the BTHS myocardial MTF constructs (Supplementary Movie 5) . Thus, LA rescued the contractile deficits of BTHS iPSC-CMs.
In addition to potentially enhancing alternative pathways of cardiolipin synthesis, LA might also influence BTHS iPSC-CM phenotype by scavenging ROS. An extensive literature implicates high levels of ROS in ischemic and hypertensive heart failure, in part through effects on sarcomere assembly and function 28 . Uncoupling of the electron transport chain and elevated mitochondrial membrane potential, both of which were observed in BTHS iPSC-CMs ( Fig. 1 and  Supplementary Fig. 14a-d) , promote mitochondrial ROS production. Indeed, we found that mitochondrial ROS production was markedly increased in BTHS iPSC-CMs, as assessed by measurement of 4-hydroxynonenal, a product of lipid peroxidation, or as assessed by MitoSOX, a mitochondrially targeted probe with ROS-enhanced fluorescence (Supplementary Fig. 14e ). 4-Hydroxynonenal levels were suppressed to near baseline by LA (Fig. 6f) . To distinguish antioxidant from cardiolipin-precursor mechanisms of LA action, we tested the mitochondrially targeted and structurally unrelated antioxidant mitoTEMPO. Like LA, mitoTEMPO suppressed excessive ROS in BTHS iPSC-CMs (Fig. 6g) .
Having confirmed that mitoTEMPO effectively suppresses excessive mitochondrial ROS in BTHS iPSC-CMs, we next determined whether mitoTEMPO treatment could improve sarcomere organization and force generation. Indeed, mitoTEMPO treatment normalized the sarcomere organization and contractility of BTHS iPSC-CMs (Fig. 6h,i and Supplementary Movie 6) . These data indicate that iPSC-CMs and heart-on-chip technology enable effective in vitro testing of candidate therapeutic agents. Furthermore, these data link impaired sarcomerogenesis and weak force generation in BTHS iPSC-CMs to excessive ROS production.
DISCUSSION
Patient-derived iPSCs have considerable potential to enhance our understanding of human disease and enable therapeutic screening on a personalized basis. However, several barriers still hinder adoption of iPSC disease models academically, clinically and commercially. One obstacle to wider use of iPSC disease models has been the genetic and epigenetic variation between cell lines, which introduces confounding variables that can be difficult to control. We show that Cas9-mediated genome editing is a useful strategy to isolate a mutation of interest and show that it is sufficient to cause a disease phenotype. Gene replacement using modRNA technology is another highly portable approach that demonstrates the acute requirement of a gene mutation for a disease phenotype within a given cell line.
Another major impediment to the use of iPSCs to study human disease pathogenesis has been the lack of in vitro models that reproduce disease pathophysiology. With respect to cardiomyopathies, modeling the contractile function of iPSC-CMs at the level of myocardial tissue has been challenging, and prior iPSC-based models of cardiomyopathy have focused on measurements of single-cell contractile function 29, 30 . Here, we assembled anisotropic laminar myocardial tissue constructs from iPSC-CMs and used these to document impaired contractile stress generation in BTHS. Furthermore, we used this approach to model phenotypic rescue at the tissue level by gene replacement and small-molecule treatments.
Our metabolic and functional analysis of human BTHS cardiomyocytes elucidated mitochondrial functional impairment caused by mature cardiolipin depletion. Our data show that the contractile . n = 3. *P < 0.05 versus control. Non-mito, the contribution of nonmitochondrial oxygen consumption to the overall cellular oxygen consumption rate ( Supplementary Fig. 5b,c) . npg deficit of BTHS iPSC-CMs is not a result of global cellular energy depletion. Rather, we show that TAZ deficiency in BTHS impairs sarcomere assembly and contractile stress generation. It is likely that sarcomere assembly is only one of several factors that lead to reduced twitch stress in BTHS iPSC-CMs, as the extent of sarcomere disarray did not necessarily correlate with impairment of twitch stress across our assays. We found that TAZ deficiency in BTHS caused markedly increased ROS production and that suppression of ROS normalized the metabolic, sarcomerogenesis and contractile phenotypes of BTHS iPSCCMs. These data indicate that excessive ROS production contributes to sarcomere disarray and reduced contractile stress generation in BTHS iPSC-CMs. ROS has been implicated in cardiomyocyte differentiation, sarcomerogenesis and contractility 18, 28 . Our data indicate that ROS scavenging may be beneficial for patients with BTHS and suggest that this strategy should be further validated using in vivo models. Our findings may be relevant to more common conditions such as ischemia and aging, as mature cardiolipin depletion and elevated ROS production also occur in these states 3 .
METHODS
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
iPSC derivation and culture. Low-passage skin fibroblasts were obtained from skin biopsies from two unrelated patients with BTHS with informed consent under protocols approved by the Boston Children's Hospital Institutional Review Board. WT1 control iPSCs were derived from BJ fibroblasts (Stemgent), and WT2 and WT3 iPSCs were described previously 7, 8, 31 . The BTH-H iPSC line was established by retroviral delivery of four reprogramming factors (OCT4, SOX2, KLF4 and Myc) 6 . The BTH-C iPSC line was established by modRNA reprogramming as described 7 . Several iPSC clones with embryonic stem cell morphology and with positive vital staining for TRA-1-81 or TRA-1-60 staining 32 were further characterized to yield the final two lines. Karyotyping was performed by Cell Line Genetics. Teratomas were formed by injection of 1 × 10 6 iPSCs intramuscularly into the flanks of adult severe combined immunodeficiency mice (Charles River Labs) under protocols approved by the Boston Children's Hospital Institutional Animal Care and Use Committee. Teratomas were examined by H&E and immunofluorescent staining. H7 human ES cells were obtained from WiCell Research Institute.
iPSC cardiac differentiation and iPSC-CM culture. Cardiomyocyte differentiation was induced as previously reported 9 , with minor modifications. Cells were detached by 3-to 5-min incubation with Versene (Invitrogen) and seeded onto Matrigel-coated plates at a density of 10,000 cells/cm 2 in mouse embryonic fibroblast conditioned medium (MEF-CM) plus 4 ng/mL human basic fibroblast growth factor (Stemgent) for 2-3 d before induction. Cells were covered with Matrigel (1:60 dilution) on the day before induction. To induce cardiac differentiation, we replaced MEF-CM with RPMI+B27 medium (RPMI-1640, 2 mM l-glutamine, ×1 B27 supplement without insulin) supplemented with 100 ng/mL of Activin A (R&D Systems) for 24 h, followed by 10 ng/mL human bone morphogenetic protein-4 (R&D) and 10 ng/mL human basic fibroblast growth factor for 4 d without culture medium changes. The culture medium was subsequently replaced with RPMI+B27 supplemented with 100 ng/mL of DKK1 (R&D) for 2 d. At day 7, the culture medium was changed to RPMI+B27 without supplementary cytokines; culture medium was refreshed every 1-2 d. Leibovitz L-15 medium was substituted for RPMI for galactose-containing culture medium. For iPSC-CM enrichment, differentiation cultures were dissociated with Accumax (Innovative Cell Technologies). Dissociated cells were stained with anti-VCAM-1 antibody (Supplementary Table 3 contains antibody information) conjugated with allophycocyanin (APC) and enriched by magnetically activated cell sorting (MACS) using anti-APC microbeads (Miltenyi Biotec). For MACS validation, sorted cells were fixed and stained with TNNT2 primary and Alexa-488-conjugated secondary antibody. Data were analyzed with FlowJo (Treestar) software. For MitoTEMPO treatment, iPSC-CMs were purified by VCAM-1 MACS and reseeded on muscle thin films at 1 million cells per well of a six-well plate (described below). The cells were treated with MitoTEMPO (Sigma) at a final concentration of 5 µM for 5 d. Linoleic acid (Sigma) was freshly prepared for each use from sealed ampules. It was dissolved in ethanol and used at a final concentration of 50 µM.
Cas9-mediated genome editing. Details of our modified Cas9-mediated genome editing strategy will be published separately. In brief, we constructed a piggyBac transposon that expresses the reverse tetracycline activator and a human codon-optimized Cas9 under the control of a tet response element. Stable transfection of PGP1-iPSCs (Coriell Institute for Medical Research) with this engineered transposon yielded PGP1-iPSC-hCas9 cells. We subsequently designed guide RNA and donor oligonucleotides (Fig. 3a-c, Supplementary  Fig. 8 and Supplementary Table 4 ) to introduce the BTH-H TAZ mutation into exon 6. After transient doxycycline administration and transfection with guide RNA and donor oligonucleotides, we screened individual clones by Sanger sequencing. We selected an unmodified clone, a clone containing the BTH-H mutation (resulting from homology-directed repair) and a clone containing an insertion resulting from nonhomologous end joining. Transient transfection with a plasmid expressing piggyBac transposase subsequently led to removal of the Cas9-containing transposon.
TAZ sequencing. TAZ sequencing was performed using previously described primers 33 Cardiac 31 P nuclear magnetic resonance. Cardiac 31 P nuclear magnetic resonance imaging was performed as described 34 with informed consent under a protocol approved by the Institutional Review Board of the Children's Hospital of Philadelphia. High-energy phosphate stores were estimated from the phosphocreatine peak area, normalized to the peak area from the β phosphate of ATP 34 .
Mitochondrial function assays.
For mitochondrial function assays, 60,000 sorted cells were seeded in 0.1% gelatin-coated Seahorse assay wells in alpha MEM (Invitrogen) with 10% FBS. They were then changed to L-15 medium supplemented with 1x B27 supplement without insulin for 5-7 d. Oxygen consumption rate (OCR) was measured using a Seahorses Biosciences XF24 extracellular flux analyzer using the Cell Mito Stress Kit (Seahorses Biosciences) and normalized to total protein, determined using the BCA protein assay (Thermo Scientific). OCR was expressed as pmol/min/10 µg protein. Based on changes OCR after addition of FCCP, oligomycin or antimycin/rotenone, we calculated the mitochondrial function metrics described in Supplementary Figure 5b ,c, as directed in the Cell Mito Stress Kit manual. For ATP assays, cells were grown in the indicated medium and supplements for 5 d. ATP assay reagent (Promega) was added directly to the wells, and light output was measured with a plate luminometer. The readout was normalized to total protein. The F 1 F 0 ATP Synthase specific activity assay was purchased from MitoSciences and used according to the manufacturer's instructions.
Mitochondrial isolation and FACS analysis.
Mitochondrial isolation and FACS analysis were performed to measure mitochondrial size, number, membrane potential and production of ROS. Mitochondrial isolation and FACS were performed based on described protocols 35 . In brief, iPSC-CMs were digested to single cells by Versene, and mitochondria were isolated using the Mitochondria Isolation Kit (Thermo Scientific). 20 million iPSC-CMs were pelleted by centrifugation at 850g for 2 min. The pellet was resuspended in 800 µl of mitochondria isolation reagent A with protease inhibitor. The suspension was vortexed at medium speed for 5 s and then incubated on ice for exactly 2 min. Next, 10 µl mitochondria isolation reagent B was added and vortexed at maximum speed for 5 s. After 5 min of incubation on ice with vortexing at maximum speed every minute, 800 µl mitochondria isolation reagent C with protease inhibitor was added. The tube was centrifuged at 700g for 10 min at 4 °C. The supernatant was transferred to a new microcentrifuge tube and centrifuged at 3,000g for 15 min. The supernatant was discarded and 500 µl mitochondria isolation reagent C was added to the pellet. The sample was then centrifuged at 12,000g for 5 min. The mitochondrial pellet was resuspended in 200 µl FACS buffer (Stemcell Technologies). Either MitoSOX (5 µM; Life Technologies) or TMRM (100 nM; Life Technologies) and MitoTracker green (50 nM; Life Technologies) were incubated with mitochondria at room temperature for 30 min. The sample was then analyzed by flow cytometry. Data were analyzed by using FlowJo software. Fluorescence intensity is reported in arbitrary units based on the readout of the FACS instrument.
NRVM culture. NRVMs were isolated from postnatal day 1 rat heart ventricles by collagenase digestion using the Neomyts isolation kit (Cellutron). Control and TAZ shRNA viruses were constructed as described previously 36 using sequences provided in Supplementary Table 4 . NRVM isolation was performed according to protocols approved by the Boston Children's Hospital Institutional Care and Use Committee.
Imaging and gene expression analysis. Immunostaining for marker expression was performed using antibodies listed in Supplementary Table 3 . Samples were fixed in 4% paraformaldehyde and permeabilized with 0.05% Triton X-100. Imaging was performed on an Olympus FV1000 or Zeiss LSM 5 LIVE confocal microscope. Quantitative RT-PCR was performed from total RNA using primers listed in Supplementary Table 4 . SYBR green chemistry was used for real-time PCR detection on an ABI 7500 instrument. Western blotting was performed using antibodies specified in Supplementary Table 3 .
Mitochondria were labeled using BacMam 2.0 mitochondria-RFP (Invitrogen), in which a baculovirus vector delivers RFP tagged with the mitochondrial localization sequence of pyruvate dehydrogenase E1 subunit α.
Electron microscopy was performed on a Tecnai G Spirit BioTWIN instrument. At least ten randomly selected fields containing cardiomyocytes were imaged per sample. npg all films were peeled, the constructs were rewarmed to 37 °C and paced with platinum field-stimulation electrodes. Films were paced at 1, 2, 3, 4 and 5 Hz, and their movement was recorded from above at 100 frames per second. Films paced at 2 Hz were used for statistical comparison because this frequency was closest to the spontaneous beat rate.
MTF stress quantitation. The longitudinal planar projections of contracting MTFs were automatically detected using custom ImageJ (NIH, Bethesda, MD) software and used to calculate the radius of curvature of each film using custom MATLAB software (Mathworks, Natick, MA), as previously described 5 . The stress of the cell layer was determined from the radius of curvature using a modified form of Stoney's equation: 
where s cell is the stress of the cell layer, E, v and t s are the Young's modulus, Poisson's ratio and thickness of the PDMS film, respectively, R is the MTF radius of curvature and t c is the thickness of the cell layer. Equation (6) can be readily derived based on the theory of the cylindrical bending of thin plates 43 and the static equilibrium of the force and torque of plate bending 44 . The plate modulus E/(1 − v 2 ) instead of the biaxial modulus E/(1 − v), appears in equation (6) because the anisotropic contraction of the cell layer bends the PDMS film into a cylindrical shape instead of a bowl-like shape. The factor (1 + t c /t s ) −1 is a correction to the standard Stoney's equation 44 when the thickness of the cell layer approaches that of the PDMS layer. We previously used a more comprehensive model 24 to calculate not only the stress in the film but also the shortening of the muscle layer. For the MTFs used in this paper, the stresses calculated by these two methods are almost identical, so we chose to adopt the simpler analytical form of the modified Stoney's equation.
Statistical analyses.
Results are reported as mean ± s.e.m. Unless otherwise indicated, we used unpaired Student's t-tests with unequal variances. Stress values failed the Shapiro-Wilkinson test for normality and were thus statistically
compared using Kruskal-Wallis one-way ANOVA on ranks and Dunn's method for pairwise comparisons. Tests with a P value less than 0.05 were considered statistically significant. No statistical method was used to predetermine sample size. The experiments were not randomized. The sarcomere organization and MTF assays were performed blinded to allocation during outcome assessment. Other experiments were not blinded to allocation during experiments and outcome assessment.
